Viatris
VTRS
About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Employees: 32,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
140% more call options, than puts
Call options by funds: $73.1M | Put options by funds: $30.5M
2.75% more ownership
Funds ownership: 80.28% [Q1] → 83.03% (+2.75%) [Q2]
4% more capital invested
Capital invested by funds: $8.34B [Q1] → $8.7B (+$360M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 330 | Existing positions reduced: 354
3% less funds holding
Funds holding: 992 [Q1] → 961 (-31) [Q2]
13% less first-time investments, than exits
New positions opened: 104 | Existing positions closed: 120
Financial journalist opinion
